Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: James Strauss who wrote (3995)	4/4/1999 3:34:00 PM
From: j g cordes	Read Replies (1) \| Respond to of 13094

Yes indeed.. we're at the dawn of something, though at times I wonder about the course we're taking to get there.

To: James Strauss who wrote (3995)	4/8/1999 8:08:00 AM
From: j g cordes	Read Replies (1) \| Respond to of 13094

Too bad this research breakthrough isn't attached to an investable company yet! If it is then you can imagine the revenue stream .. "Wednesday April 7 1:29 PM ET New urine test may detect cancer NEW YORK, Apr 07 (Reuters Health) -- Scientists are working on a urine test that may not only detect cancer, but also provide information about the type and stage of a patient's tumor, according to a report in the journal Analytical Chemistry. Dr. Yinfa Ma of Truman State University in Kirksville, Missouri, and colleagues at the Chinese Academy of Sciences in Dalian, China, have developed a method to quickly measure levels of chemicals called pteridines in the urine. Pteridines play an important role in metabolism of cells, including the synthesis of certain vitamins such as vitamin B2. But malignant tumors ''greatly disturb the biosynthesis and metabolism of pteridines, thus leading to a great change in pteridine concentrations'' the investigators report. Using their new testing methods, Ma and colleagues found that cancer patients who have not undergone chemotherapy have significantly higher levels of these chemicals in their urine than healthy people. In a study of 19 people, the urine test was able to correctly identify the 9 individuals who had been diagnosed with cancer but not yet treated. ''The investigation on normal 'control' (patients) and various cancer patients showed that there existed a significant difference in pteridine concentrations among the two groups, which indicated that pteridine level may be an important factor for the diagnosis of cancer,'' Ma notes in a statement from the American Chemical Society. The next step is to try to determine each cancer's unique pteridine signature. ''Each type of tumor shows its own pattern in changes of pteridine concentrations,'' Ma adds, ''since different pteridine derivatives may play various roles in different tumor-related disease.'' Ma and colleagues acknowledge that more data is needed to reach a solid conclusion about the diagnostic value of pteridine levels, but they claim the new technique ''does provide a convenient method for further investigation.'' The testing technique developed by Ma's team uses high-performance capillary electrophoresis, in which particles are filtered through a gel and laser-induced fluorescence detection, which uses light to identify compounds. Until the development of this new technique, determining pteridine levels has been costly, time-consuming, and not very accurate. SOURCE: Analytical Chemistry 1999;1262-1269."